Study S002327

Study of Endothelial Glycocalyx and Vascular Function in Patients With Type 2 Diabetes and Albuminuria After Administration of Dulaglutide and Dapagliflozin vs DPP-4 Inhibitors

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT06611904
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: NONE
Status: UNKNOWN
Enrollment: 60
Start: 2018-02-01
Primary completion: 2022-02-05
Lead sponsor: Attikon Hospital
Conditions: Urine Albumin (UAlb); Glycocalyx; Arterial Stiffness
Interventions: DRUG:Dulaglutide; DRUG:DPP-4 Inhibitors
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

UACR [4 and 12 months]
PWV [4 and 12 months]
PBR [4 and 12 months]
GLS [4 and 12 months]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0018551	Dulaglutide and Dapagliflozin Combination Concurrently Improves the Endothelial Glycocalyx and Vascular and Myocardial Function in Patients with T2DM and Albuminuria vs. DPP-4i. Korakas E, Journal of clinical medicine	2024	Randomized trial	PMID 39768420 DOI	cites ClinicalTrials.gov:NCT06611904; registry reference DERIVED:39768420
R0016601	Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes. Lambadiari V, Cardiovascular diabetology	2018	Randomized trial	PMID 29310645 DOI	registry reference RESULT:29310645